JUN 13, 2016 3:01 PM PDT

Personalized Treatment For People With Depression?

WRITTEN BY: Xuan Pham
Depression affects millions of people worldwide, yet it’s an illness that’s still highly stigmatized. As with many illnesses, some patients respond to treatment and some don’t. But a new research suggests that testing patients for inflammatory biomarkers could reveal those who could benefit from more aggressive medication regimen.
    First of its kind test could personalize depression treatment | pixabay.com
 Clinical depression is different than sadness following a traumatic life event, such as the loss of a loved one. Patients with clinical depression are diagnosed by trained physicians based on criteria set by the Diagnostic and Statistical Manual of Mental Disorders (DSM). Currently, an estimated 14.8 million Americans are afflicted with depression. And as the mental condition is tied to physical wellness, the incidence of depression is ever increasing.
 
Generally, patients with depression are treated with a combination of medication (antidepressants) and psychological counseling. But the success rate of these treatments is variable, and doctors often have to engage through trial and error to arrive at the correct medication dose for their patients. Could blood-borne biomarkers eliminate this trial and error?
 
Based on the belief that inflammation drives stress which interferes with the actions of antidepressants, researchers at the King’s College London wondered whether inflammatory proteins could point to hard-to-treat cases. They looked at 140 people with depression, and isolated two biomarkers of inflammation: macrophage migration inhibitory factor (MIF), and interleukin-1beta.
 
In their study, the researchers found presence of these two biomarkers corresponded with decreased response to treatment. That is, patients with high levels of these proteins were less likely to respond to traditional antidepressants like selective serotonin reuptake inhibitors (SSRIs) and tricyclic compounds.
 

"About a third of patients might have these inflammatory markers and they would be people we might encourage to go on more aggressive treatment," said Carmine Pariante, the senior study author.
 
By contrast, the biomarker could alert doctors to go easy on those who are more likely to respond to the medications. After all, antidepressants may be safe, but they are not without side-effects. "We would not want to go in prescribing too much medicine if it's not necessary, but we would want to escalate people sooner rather than later if they need it," said Pariante.
 
Some caveats of the study include the limited size and the need for validation in a larger clinical trial. But the team is excited, as this is the first study of its kind to point towards personalized therapy for a mental illness like depression. "Being able to target those people with depression who don't respond to medication would be one of the most exciting steps forward in the treatment of mental illness for decades," said Marjorie Wallace, chief executive of SANE, a UK mental health charity organization.

Additional source: BBC
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 12, 2020
Cancer
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
AUG 12, 2020
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
Since the 1940s, chemotherapy has been a primary treatment option for cancer. The late 20th century brought a new type o ...
AUG 23, 2020
Technology
Cyborg Technology Could Advance Diagnostics
AUG 23, 2020
Cyborg Technology Could Advance Diagnostics
Although it’s true, "cyborgs" are technically science fiction being the fact that they are part human an ...
SEP 10, 2020
Clinical & Molecular DX
Microscope to Diagnose River Blindness Is a Winner
SEP 10, 2020
Microscope to Diagnose River Blindness Is a Winner
  A team of innovators from Stanford University has invented the Onchoscope: a low-cost, customizable microscope fo ...
SEP 07, 2020
Cell & Molecular Biology
With Nanopores, Small Samples Detect Diseases
SEP 07, 2020
With Nanopores, Small Samples Detect Diseases
If you've ever been through a battery of tests while doctors try to find a diagnosis for an ailment, you know that many ...
OCT 02, 2020
Clinical & Molecular DX
Detecting Dystonia in the Blink of an AI
OCT 02, 2020
Detecting Dystonia in the Blink of an AI
A team of scientists have created a diagnostic tool, powered by artificial intelligence (AI), that can pick up on the su ...
NOV 14, 2020
Cannabis Sciences
Half of CBD Users Test Positive for THC in Urine Tests
NOV 14, 2020
Half of CBD Users Test Positive for THC in Urine Tests
Despite the growing popularity of cannabidiol (CBD) products, there has been little research directly assessing whether ...
Loading Comments...